BICTFBiocure Technology Inc.

About Biocure Technology Inc. (BICTF)

Biocure Technology Inc. (BICTF) is a Biotechnology company headquartered in Vancouver, BC, Canada whose shares trade over-the-counter on the Pink tier.

Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.

Products and services

Biocure Technology Inc. is a research stage biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.

BICTF key facts

Ticker symbol

BICTF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Vancouver, BC, Canada

Country of incorporation

CA

Year of incorporation

2007

Employees

15

Estimated market cap

$14.6K (as of May 9, 2025)

Shares outstanding

10,444,474

Reporting standard

International Reporting: Canadian Securities Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Interim Financial Report (Sep 30, 2021)

Biocure Technology Inc. leadership

• Sang Mok Lee — CEO
• Bjorn Cochlovius — President
• Konstantin Lichtenwald — CFO

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with B